Study reveals male sex hormones are new targets for cancer immunotherapy

Read the Story

Show Top Comments

Patients with cancers stemming from non-reproductive organs, such as bladder and liver cancer, have striking discrepancies in incidence, progression, response to treatment and survival outcomes depending on their sex. In almost all cases, male patients have worse prognoses and outcomes. This phenomenon has puzzled the scientific community for decades. The focus of this research was the T cell immune response to malignancy, a key determinator of outcomes in cancer, and an important target that has contributed to the renaissance of cancer immunotherapy seen in recent years. The study reported a landmark finding that describes how male sex hormones contribute to cancer-related sex bias via the modulation of CD8+ T cells — a population of cells often referred to as cancer “killer” cells, which mediate adaptive immunity and are critical for mounting an anti-tumor response.


My grandmother was treated with male hormones for breast-to-bone cancer in the early 1960s. Part of a trial at the Mayo Clinic. It produced male-pattern hair growth (she eventually had to start shaving, a humiliating thing for a demure farm wife). It didn’t change the course of the disease, and she endured a prolonged and tortuous death, but she felt good about possibly contributing to eventual effective treatments. She died in 1961.


Come on baby, put on Barry White and let’s cure some cancer


Thanks for this artical. I have been researching new immunotherapy for my bladder cancer.


Would hormone blockers help against the testosterone and other hormones worsening the cancer?